{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:32:42Z","timestamp":1793165562989,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijrobp.2026.10.017","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:17:07Z","timestamp":1792772227000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET-Guided Dose Escalation for Stage III Non-Small Cell Lung Cancer: A Randomized Clinical Trial"],"prefix":"10.1016","author":[{"given":"Srinivas","family":"Raman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harroun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Taremi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bezjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dagnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Emile","family":"Plourde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Melody","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy-Anne","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Yaremko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Gaede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.10.017_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","author":"Spigel","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.017_bib0002","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2019.08.034","article-title":"Faivre-Finn C. Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC)","volume":"105","author":"Raben","year":"2019","journal-title":"International Journal of Radiation Oncology"},{"issue":"7","key":"10.1016\/j.ijrobp.2026.10.017_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"Journal of clinical oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.017_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.radonc.2009.01.003","article-title":"Is pre-therapeutical FDG-PET\/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?","volume":"91","author":"Abramyuk","year":"2009","journal-title":"Radiotherapy and oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.017_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2009.03.006","article-title":"Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan","volume":"91","author":"Aerts","year":"2009","journal-title":"Radiotherapy and oncology"},{"issue":"5","key":"10.1016\/j.ijrobp.2026.10.017_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.05.002","article-title":"Rationale and protocol for a Canadian multicenter phase II randomized trial assessing selective metabolically adaptive radiation dose escalation in locally advanced non\u2013small-cell lung cancer (NCT02788461)","volume":"19","author":"Raman","year":"2018","journal-title":"Clinical lung cancer"},{"issue":"5","key":"10.1016\/j.ijrobp.2026.10.017_bib0007","article-title":"Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study","volume":"71","author":"Aerts","year":"2008","journal-title":"International Journal of Radiation Oncology*"},{"key":"10.1016\/j.ijrobp.2026.10.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"Van Diessen","year":"2019","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.ijrobp.2026.10.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiotherapy and Oncology"},{"issue":"17","key":"10.1016\/j.ijrobp.2026.10.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01386","article-title":"Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non\u2013Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial","volume":"43","author":"Schytte","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.ijrobp.2026.10.017_bib0011","article-title":"Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non\u2013small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing","volume":"73","author":"Feng","year":"2009","journal-title":"International Journal of Radiation Oncology*"},{"issue":"33","key":"10.1016\/j.ijrobp.2026.10.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo) radiotherapy using midtreatment 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non\u2013small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.ijrobp.2026.10.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F] FDG-PET tumour residual uptake at 42 Gy (RTEP7\u2013IFCT-1402): a multicentre, randomised, controlled phase 2 trial","volume":"25","author":"Vera","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.017_bib0014","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ijrobp.2020.07.2286","article-title":"Individualized adaptive radiotherapy versus standard radiotherapy with chemotherapy for patients with locally advanced Non-small Cell Lung Cancer: a multicenter randomized phase III clinical trial CRTOG1601","volume":"108","author":"Yuan","year":"2020","journal-title":"International Journal of Radiation Oncology"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.10.017_bib0015","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ijrobp.2023.06.288","article-title":"Adaptive radiotherapy guided by PET\/CT in patients with locally advanced non\u2013small cell lung cancer: a phase II randomized study","volume":"117","author":"Zhu","year":"2023","journal-title":"International Journal of Radiation Oncology"},{"issue":"5","key":"10.1016\/j.ijrobp.2026.10.017_bib0016","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: A systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"International Journal of Radiation Oncology*"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.10.017_bib0017","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"International Journal of Radiation Oncology*"},{"key":"10.1016\/j.ijrobp.2026.10.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.ijrobp.2026.10.017_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2022.10.019","article-title":"Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy","volume":"177","author":"Venkatesulu","year":"2022","journal-title":"Radiotherapy and Oncology"},{"issue":"6","key":"10.1016\/j.ijrobp.2026.10.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"10.1016\/j.ijrobp.2026.10.017_bib0021","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.ijrobp.2026.10.017_bib0022","article-title":"Prognostic and predictive role of PD-L1 expression in stage III non-small cell lung cancer treated with definitive chemoradiation and adjuvant durvalumab","volume":"113","author":"Bryant","year":"2022","journal-title":"International Journal of Radiation Oncology*"},{"issue":"10","key":"10.1016\/j.ijrobp.2026.10.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clinical cancer research"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:46:06Z","timestamp":1793162766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626043828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S0360301626043828"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.10.017","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET-Guided Dose Escalation for Stage III Non-Small Cell Lung Cancer: A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}